A chaotic FDA is incompatible with a thriving, competitive market for medical discovery. Any effort to reform the agency must prioritize removing barriers and avoiding delays that keep safe, effective medicines from reaching patients.
Chaos has become the norm at the U.S. Food and Drug Administration. And it’s putting American patients, not to mention our country’s world-leading life sciences sector, at risk.
Earlier this year, roughly 3,500 FDA employees were laid off. The agency’s Center for Drug Evaluation and Research, which oversees prescription and over-the-counter drugs, will soon be on its third leader since November. Last month, the FDA signaled that it may subject vaccines to stricter approval requirements—without providing evidence explaining why.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Chaos At The FDA Benefits America’s Rivals—At The Expense Of America’s Patients
Sally C. Pipes
A chaotic FDA is incompatible with a thriving, competitive market for medical discovery. Any effort to reform the agency must prioritize removing barriers and avoiding delays that keep safe, effective medicines from reaching patients.
Chaos has become the norm at the U.S. Food and Drug Administration. And it’s putting American patients, not to mention our country’s world-leading life sciences sector, at risk.
Earlier this year, roughly 3,500 FDA employees were laid off. The agency’s Center for Drug Evaluation and Research, which oversees prescription and over-the-counter drugs, will soon be on its third leader since November. Last month, the FDA signaled that it may subject vaccines to stricter approval requirements—without providing evidence explaining why.
Read the entire op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.